Kenvue Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Kenvue reported Q2 2026 net sales of $3,955M (up 3.0% YoY) with organic sales growth of 1.6%, driven by 0.9% price/mix and 0.7% volume gains. Diluted EPS increased 9% to $0.24; adjusted diluted EPS rose 7% to $0.31. All three segments showed organic growth. The company announced FDA approval for Tylenol with Naproxen (first OTC fixed-dose acetaminophen/naproxen combination) with three-year exclusivity. The pending Kimberly-Clark acquisition remains on track for Q4 2026 close; Kenvue suspended forward guidance and is not hosting a quarterly call due to the transaction.
Why this rating
Routine quarterly beat vs. modest guidance; strong execution offset by pending acquisition uncertainty and margin compression from inflation/tariffs. Material but ordinary for a $39.6B company.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.